Title: A sensitive multiplex RT-qPCR assay to detect SARS-CoV-2 in respiratory samples

Authors: Alice Halliday[1,2,#,$], Begonia Morales-Aza[1,2,#], Kaltun Duale[1,2, #], Philippa Lait[3,4], Bristol Vaccine Centre Microbiology & Molecular Laboratories*, Rachel Milligan[2], Stephanie Hutchings[5], Hannah Pymont[5], Barry Vipond[5], Peter Muir[5], Christy Waterfall[6], Jane Coghill[6], Jeremy Carr[7], Emma Plested[7], Jennifer Oliver[1,8], Katy Fidler[9,10], Caroline Relton[11,12], Matthew D Snape[7,13] on behalf of the 'Be on the Team' Investigators*, Andrew D. Davidson[2], Christopher Helps[3,4], & Adam Finn[1,2,8,14].

Affiliations:

1 – Bristol Vaccine Centre, University of Bristol

2 – School of Cellular and Molecular Medicine, University of Bristol.

3 - Langford Vets, University of Bristol

4 – School of Veterinary Sciences, University of Bristol

5 - UK Health Security Agency (UKSHA)

6 - Genomics Facility, Faculty of Health & Life Sciences, University of Bristol

7 - Oxford Vaccine Group, University of Oxford Department of Paediatrics.

8 - Population Health Sciences, Bristol Medical School, University of Bristol, UK

9 - Brighton and Sussex Medical School, Falmer, UK

10 - Royal Alexandra Children's Hospital, University Hospital Sussex NHS Foundation Trust

11 - MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, UK

12- London School of Hygiene & Tropical Medicine, London, UK

13 - Oxford NIHR Biomedical Research Centre.

14 - Paediatric Immunology and Infectious Diseases, Bristol Royal Hospital for Children

*See Appendix 1 for a full list of investigators from both the BVC Microbiology and Molecular Laboratories and from the 'Be on the Team' Investigators.

# These authors contributed equally

$ Corresponding author: alice.halliday@bristol.ac.uk

Abstract

We developed an in-house RT-qPCR assay for the detection of SARS-CoV-2 from different sample types. Novel primer and probe sets were designed to amplify 2 regions of the nucleocapsid (N) gene. Two dual-target multiplex assays were then evaluated for performance in detection of SARS-CoV-2 in known samples. An assay combining one novel primer pair for N (N6), a published region for the envelope protein (E) and an extraction control target (MS2), was found to have good efficiency and a low limit of detection, and to be sensitive and specific for SARS-CoV-2 in a sample set of known positive and negative clinical samples. Assay performance was maintained for the main variants of concern (Alpha, Delta, Gamma and Omicron BA.1, BA.2, BA4, JN.1). The assay was used to test for SARS-CoV-2 in throat swab samples collected in schools from teenagers in the UK as part of an observational study of two Meningococcal B Vaccines in Jan-March 2020. The low prevalence of positives identified (0.44-0.47% in two weeks of March 2020) suggests that there was minimal circulation of SARS-CoV-2 in UK schools prior to the first lockdown. The N6/E/MS2 assay has since been used to detect SARS-CoV-2 in samples from multiple studies. Continual monitoring will ensure that performance of this novel multiplex assay is maintained as novel sub-variants emerge.

45 **Introduction**

46 The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes
47 coronavirus infectious disease 2019 (COVID-19) has led to a pandemic with severe health, social and
48 economic consequences globally. Some early attempts to establish diagnostic PCR assays to detect
49 SARS-CoV-2 using a range of gene targets including those encoding the RNA-dependent RNA
50 polymerase (RdRp) and nucleocapsid (N), envelope (E) and Spike (S) proteins (1, 2) were only
51 moderately successful with relatively low sensitivity and significant numbers of false negatives.
52 Subsequently a range of high performing assays have been developed and deployed by government
53 and academic labs and numerous commercial assays have also become available.

54 Lateral flow antigen tests, which are less sensitive but reasonably predictive of infectiousness have
55 the important advantages of low cost, rapid results with no requirement for laboratory processing
56 and have been widely deployed to support public health efforts to control spread of the infection.
57 Nevertheless, RT-qPCR remains the gold standard testing methodology for individual diagnosis of
58 SARS-CoV-2 infection with high sensitivity and specificity.

59 Here we describe development, evaluation and deployment of a novel SARS-CoV-2 RT-qPCR assay
60 which uses Envelope (E) and Nucleocapsid (N) gene targets and delivers high technical and
61 diagnostic performance. We also present data from the testing of throat swabs samples collected
62 from teenagers in England in early 2020, at the very start of the UK SARS-CoV-2 epidemic.

63

64 **Methods**

65 ***Samples, Ethics and Consent***

66 Frozen SARS-CoV-2 positive and negative nasopharyngeal/oropharyngeal swabs (NPS/OPS) in viral
67 transport medium (VTM) collected in early 2020 were taken from individuals undergoing testing for
68 SARS-CoV-2 across the Bristol area. These were tested at Severn Pathology Laboratories, Bristol, UK

69 Health Security Agency (UKHSA), and anonymised remnant samples and laboratory test data were
70 subsequently transferred to the University of Bristol to assist in the validation of two candidate RT-
71 qPCR assays.

72 For field testing the assay on unknown samples, oropharyngeal swabs (OPS) from healthy 16–17-
73 year-olds enrolled in the "Be on the Team" (BOTT) study were used. This was a large vaccine study in
74 progress at the time evaluating the impact of two protein antigen meningococcal vaccines (Bexsero
75 (GSK) and Trumenba (Pfizer)) on respiratory carriage (3, 4). Signed informed consent was obtained in
76 all cases for surplus material from swab samples to be used for additional research and permission
77 to use them for detection of SARS-CoV-2 was obtained from the ethics committee who first
78 approved the parent study before this work was done (18/SC/0055). Oropharyngeal swabs were
79 collected into 1.5 mL skim milk, tryptone, glucose, and glycerin (STGG) broth (E&O Laboratories)
80 from BOTT at sites in 16 regions across the UK between January and March 2020. These swabs were
81 shipped to the Bristol laboratories for total nucleic acid extraction and RT-qPCR.

82 Positive control material for SARS-CoV-2 Delta and Omicron strains were obtained with appropriate
83 informed consent via Bristol Biobank (20/WA/0273), from infected adult volunteer donors working
84 in the Biomedical Sciences Building, University of Bristol. Collected specimens were held at 4°C and
85 transported to the laboratories before freezing at -70 °C within 4 hours.

86 ***Extraction***

87 Samples were kept frozen at –70 °C and were defrosted on ice prior to nucleic acid extraction. All
88 samples were first vortexed for 30 seconds, then chemically inactivated by adding 500 µL of L6
89 Buffer (Severn Biotech, 20-8600-15) to 90 µL sample (on ice), then vortexed for a further 3 seconds
90 and incubated at room temperature for 15 minutes (as per UKHSA Guidelines). Positive and negative
91 samples provided by UKHSA and BOTT samples underwent nucleic acid extraction using the
92 QIAsymphony DSP Virus/Pathogen Mini Kit (QIAGEN), in combination with the QIAsymphony SP
93 instrument, according to the manufacturer's instructions (Extraction Protocol: Cell_Free 200 with

94 elute volume of 60 µl). Additional extraction protocols (i.e. Macherey Nagel Nucleospin RNA Kit;
95 Kingfisher) were also used and compared for extraction of RNA from control materials and found to
96 provide comparable results to the QIASymphony (results not shown). For all extractions, samples
97 were spiked with the RNA bacteriophage MS2 (genome accession V00642.1, provided by Langford
98 Vets) at a final dilution of 10^{-8} of a lab grown stock to give a CT value of ~24. This was used as an
99 internal control for the extraction process, RT and qPCR.

100 ***RT-qPCR Assay Design and Initial Optimisation***

101 With the exception of the E gene, where primer and probe sequences were unchanged from those
102 described previously (5), RT-qPCR assays and novel primers were designed for different genes of
103 SARS-CoV-2 as previously described (6), with details provided in Table 1. Novel SARS-CoV-2 primers
104 and probes from different regions of the nucleocapsid (N gene; denoted N2 and N6 (in-house
105 numbering)) were designed using Primer3 (7) using a consensus multiple sequence alignment of 658
106 SARS-CoV-2 N gene sequences downloaded from GenBank (sequences downloaded April 2020 and
107 Alignments performed in May 2020). Amplicon secondary structure was predicted using Mfold (8).

108 One fluorophore/quencher combination (FAM-BHQ-1) was included for the probe of each of the
109 SARS-CoV-2 target genes. SARS-CoV-2 primer/probes were multiplexed in pair combinations with
110 MS2 bacteriophage primers and probe (with a Cy5-BHQ3 fluorophore/quencher) to allow for
111 detection of an internal extraction control. All primers and probes were HPLC purified and ordered
112 from Metabion Ltd. (Germany).

113

114

115

116

117

118 **Table 1. Primer and Probe Sequences. Full sequences and modifications for primers and**
119 **probes in the SARS-CoV-2 N6/E/MS2 Multiplex Assay as well as the final concentration used in**
120 **RT-qPCR. * Position indicated is relative to SARS-CoV-2 isolate Wuhan-Hu-1 genome (accession**
121 **MN908947.3) or MS2 phage genome (accession V00642.1). Probes were labelled with 6-**
122 **Carboxyfluorescein (6-FAM) and Black Hole Quencher 1 (BHQ1) or Cyanine 5 (CY5) and Black**
123 **Hole Quencher 3 (BHQ3).**

Name	Position *	Sequence (5'-3')	Concentration used in RT-qPCR
CoV2_N2_F	28499-28520	ACCAATAGCAGTCCAGATGACC	200nM
CoV2_N2_R	28560-28583	GATCTTTCATTTTACCGTCACCAC	200nM
CoV2_N2_P	28534-28559	6-FAM-CCGAAGAGCTACCAGACGAATTCGTG -BHQ-1	100nM
CoV2_N6_F Forward Primer	28919-28938	GATGCTGCTCTTGCTTTGCT	200nM
CoV2_N6_R Reverse Primer	28980-29001	CCTTGTTGTTGTTGGCCTTTAC	200nM
CoV2_N6_P Probe (FAM)	28940-28968	6-FAM-CTGCTTGACAGATTGAACCAGCTTGAGAG-BHQ-1	100nM
E_Sarbeco_F1 Forward Primer	26269-26294	ACAGGTACGTTAATAGTTAATAGCGT	200nM
E_Sarbeco_R2 Reverse Primer	26360-26381	ATATTGCAGCAGTACGCACACA	200nM
E_Sarbeco_P1 Probe (FAM)	26332-26357	6-FAM- ACACTAGCCATCCTTACTGCGCTTCG-BHQ-1	100nM
MS2 F Forward primer	2163-2180	ATGGGGCACAAGTTGCAG	50nM
MS2 R Reverse primer	2226-2245	GGGTAACGGTTGCTTGTTCA	50nM
MS2 P Probe (CY5)	2183-2206	Cy5-TGCAGCGCCTTACAAGAAGTTCGC-BHQ-3	50nM

124

125 A one-step RT-qPCR assay was used for all candidate target combinations, where each reaction well
126 contained 6.25 µL TaqPath 1- Step RT-qPCR Master Mix, CG (ThermoFisher Scientific), 1 µL of 25X
127 primer and probe mix, 7.75 µL molecular grade water and 10 µL total nucleic acid extract. Each RT-
128 qPCR run contained the following controls: nucleic acid extracted SARS-CoV-2 positive control of the
129 ancestral Wuhan strain (1:10,000 dilution; see Table 2 below); extracted L6 Buffer (negative control);
130 molecular grade water (W4502-1L, Sigma-Aldrich; non-template control).

131 Total nucleic acid and master mixes were pipetted using the automated QIAgility HEPA / UV
132 Instrument (QIAGEN) before being run on the QuantStudio 7 Real-Time PCR System (Applied
133 Biosystems). Thermal cycling consisted of 25°C for 2 mins, 50°C for 15 mins and 40 cycles of 95°C for
134 10 sec, 60°C for 30 sec (as per guidelines for TaqPath, ThermoFisher Scientific).

135 ***Reaction Efficiencies and Limit of Detection***

136 Reaction efficiencies were determined using dilutions of SARS-CoV-2 ancestral strain (Wuhan, see
137 Table 1) RNA purified from tissue culture supernatant of SARS-CoV-2 infected cells as described
138 previously (9). Limit of detection (LoD) was determined using RNA extracted from a commercial
139 source of synthetic SARS-CoV-2 of known copy number (AccuPlex SARS-CoV-2 reference material,
140 4162 copies/ml, SeraCare Life Sciences Inc, USA). Purified RNA was diluted two-fold and between 8
141 and 16 replicates run at each dilution.

142 ***Sensitivity and Specificity***

143 Diagnostic sensitivity and specificity were determined using a panel of 60 SARS-CoV-2 positive and
144 59 SARS-CoV-2 negative samples kindly supplied by UKSHA Bristol and previously tested in their
145 laboratories using a commercial kit (RealStar®SARS-CoV-2 RT-PCR Kit 1.0, Altona Diagnostics,
146 Hamburg), which acted as the reference standard. To calculate confidence intervals for sensitivity
147 and specificity values, the Clopper-Pearson method was used.

148 ***SARS-CoV-2 Variants and Sequencing***

149 To test the performance of the N6/E/MS2 and N2/N6/MS2 assays on different SARS-CoV-2 variants,
150 viruses were obtained from multiple sources; details of these are provided in Table 2. In all cases,
151 the specific strain ID was determined using Illumina mRNA sequencing (performed by staff at the
152 Genomics Facility, University of Bristol) using the following kits/methods. A total volume of 8ul of
153 total RNA sample was taken directly into the NEBNext® Artic SARS-CoV-2 Library Prep Kit Part
154 Number E7650S/L (New England Biolands, Inc. Ipswich, MA) or the NEBNext® Artic FS SARS-CoV-2
155 Library Prep Kit Part Number E7658S/L followingthe manufacturer's instructions without deviation.

156 Briefly, the protocol involved cDNA synthesis, followed by targeted cDNA amplification using two
157 primer pair pools, A and B, to span the SARS-CoV-2 virus genome (primer schemes based on the
158 original work of the ARTIC Network (https://github.com/joshquick/artic-
159 ncov2019/blob/master/primer_schemes/nCoV-2019/V3/nCoV-2019.tsv). Primer schemes evolved
160 throughout the running of this experiment and the latest version was used to represent current
161 variants. Resulting amplicons from the two PCRs (A and B) per sample were pooled and cleaned up
162 using a bead-based method (beads supplied in library preparation kit) before checking resulting
163 amplicon size (1 in 10 dilution) on the Agilent TapeStation High Sensitivity DNA 1000 Screentape
164 Assay (Agilent Technologies, Santa Clara, CA) on the Agilent 2200 TapeStation instrument. The
165 amplicons were end-repaired prior to NEBNext 'Adaptor for Illumina' ligation, a further bead-based
166 clean-up, PCR enrichment of the adaptor-ligated DNA to incorporate a unique dual-index barcode
167 into each sample, and a final bead-based clean-up of the final libraries.

168 Final libraries were quantified using the Thermofisher High Sensitivity dsDNA Qubit assay
169 (Thermofisher Scientific, Inc., Waltham, MA) and validated using the TapeStation (Agilent) High
170 Sensitivity DNA1000 screentape assay on the Agilent 2200 TapeStation instrument. The libraries
171 were normalised to 4nM, pooled equimolarly, and diluted to 10pM for sequencing on the Illumina
172 MiSeq instrument using an Illumina Version 3, 600-cycle sequencing kit (Illumina Inc, San Diego, CA)
173 and MiSeq Control Software Version 2.5.0.5. A spike-in of a PhiX control library Version 3 (Illumina
174 Inc., San Diego, CA) at 10 percent was added to the sequencing run to assist with accurate base
175 calling for a biased library. Primary data analysis was completed by on-board MiSeq Software (RTA
176 Version 1.18.54.0) and FASTQ Creator (MiSeq Reporter Version 2.5.1.3). Data visualisation and QC
177 metrics were assessed using Illumina BaseSpace Sequence Hub (basespace.illumina.com).

178

179

180 **Table 2. Details of sequences and sources of the various SARS-CoV-2 strains used to**
181 **validate RT-qPCR assays and as positive control material.**

Strain name	Details of Strain ID/sequence/annotation	Source
Ancestral strain (Wuhan)	REMRQ0001 GenBank accession number MW041156.1	Isolated in April, 2020 as previously described (9)
Alpha	hCoV-19/England/204690005/2020; GISAID ID: EPI_ISL_693401;	Kindly provided by Professor Wendy Barclay, Imperial College, London and Professor Maria Zambon, UK Health Security Agency
Delta	hCoV-19/England/BRS-UoB-233/2021; GISAID ID: EPI_ISL_15250227,	Isolated from a donor sample as previously described (10)
Gamma	hCoV-19/England/520336_B1_P0/2021, GISAID ID: EPI_ISL_2080492	
Omicron BA.1	hCoV-19/England/BRS-UoB-942/2022; GISAID ID: EPI_ISL_18150332	Isolated from donor sample obtained from the Bristol Biobank
Omicron BA.2	hCoV-19/England/BRS-UoB-317/2022; GISAID ID: EPI_ISL_18303155	Isolated from donor sample obtained from the Bristol Biobank
Omicron BA.4	hCoV-19/England/BRS-UoB-64/2022; GISAID ID: EPI_ISL_18151340	Isolated from donor sample obtained from the Bristol Biobank
Omicron JN.1	Only Spike gene sequence and confirmed to have JN.1 lineage defining mutations.	Isolated from donor sample obtained from the Bristol Biobank

182

183 Positive samples identified from the field testing of BOTT OPS collected in 2020, were sequenced
184 and strain-typed in Exeter by COG-UK using MinION sequencing as described in the published
185 protocol (11).

186 ***Data Analysis***

187 Data analysis and presentation were performed with GraphPad Prism (v10). The limit of detection
188 was defined as the copy number at which >95% of replicates were detected, as determined by fitting
189 a 4 parameter logistic regression (least squares fit) on a plot of fraction samples positive against
190 known copies of virus per RT-qPCR, and interpolating the value (and 95% confidence intervals where
191 fraction positive = 0.95). RT-qPCR data from test samples were exported using either the
192 QuantStudio Real-Time PCR Software v1.3 or the Qtower3. Any CT in the FAM channel for candidate

193 assays indicated SARS-CoV-2 RNA had been detected. Cut-off values were determined using
194 multiple repeats of serial dilutions of positive control material, and for all assays CT values <=35
195 were considered positive. Thresholds were set to 0.01 for SARS-CoV-2 N6 and E, which are
196 indistinguishable since they both use the FAM channel and 0.01 for the MS2 bacteriophage used the
197 Cy5 channel.

198

199 **Results**

200 ***Initial characterisation of N6/E/MS2 and N2/N6/MS2 RT-qPCR assays***

201 We initially developed single plex assays to detect different genes from the SARS-CoV-2 genome,
202 including two areas of the gene for nucleocapsid (N2, N6) and one each of envelope (E) and the RNA-
203 dependent-RNA-polymerase (RdRp). Of these potential targets, primers binding to the E and N genes
204 were found to provide the best efficiencies (data not shown). Two candidate dual target assays were
205 developed, to improve on the sensitivity over single plex assays), including incorporation of control
206 target (MS2) to assess for extraction, RT and qPCR performance. The candidate assays selected for
207 further characterisation were: N6/E/MS2 and N2/N6/MS2.

208 We sought to determine limits of detection (LoD) and reaction efficiencies of the two candidate
209 assays, using the ancestral (Wuhan) SARS-CoV-2. Both assays showed suitable efficiencies as
210 multiplex assays and were compared to use of the targets in a single plex assay (Supplementary
211 Figure 1). However, the N2/N6/MS2 assay had a greater reaction efficiency at 98% with R^2= 0.995,
212 compared to N6/E/MS2 at 95% (R^2=0.998) (Supplementary Figure 1). The LoD was determined using
213 multiple aliquots of samples with known copy numbers (Figure 1) and was defined as the copy
214 number at which 95% of replicates were detected.



Figure 1. Limit of detection (LoD) was determined using RNA extracted from a commercial source of synthetic SARS-CoV-2 of known copy number (Accuplex SARS-CoV-2 reference material, 4162 copies/ml, Seracare Life Sciences Inc, USA). Purified RNA was diluted two-fold and between 8 and 16 replicates were run at each dilution. A) N6/E/MS2 and B) N2/N6/MS2 plots show the RNA copies per reaction on the axis and the % positive readings on each assay on the y axis with a curve plotted using 4 parameter logistic regression (least squares) with 90% confidence intervals also plotted. The LoD is defined as the copy number of virus at which 95% of replicates are detected as determined by interpolating the values when the fraction positive =0.95; these are stated in a panel within each plot, along with the R squared (R^2) for each assay.

The N6/E/MS2 assay displayed a lower LoD of 1.39 RNA copies per RT-qPCR (1.25-1.55, 90% CI) compared to N2/N6/MS2 at 2.79 (1.87 –6.35, 90% CI). At the highest dilution of virus at 0.65 copies per 10 µl reaction, the N6/E/MS2 assay detected almost double the number of positive results with very low viral copies compared to N2/N6/MS2 assay (75% compared to 37.5%).

Sensitivity and Specificity

To determine assay performance of the two candidate assays, we performed a blind comparison with a gold standard dual target RT-qPCR kit which was commonly used at the time of assay development (2020), the Altona kit for monoplex detection of the S and E genes. Using a randomised set of 60 positive and 59 negative dual NPS and OPS samples provided by UKHSA Bristol (Severn Pathology, Southmead Hospital), we extracted RNA and tested the two candidate RT-qPCR assays. Both assays had high sensitivity for the positive samples (98.33% (59/60) for N6/E/MS2 and 96.7% (58/60) for N2/N6/MS2), and 100% (59/59) specificity, see Table 3).

240 **Table 3. Diagnostic performance of candidate RT-qPCR assays. The sensitivity and**
241 **specificity of the N6/E/MS2 and N2/N6/MS2 assays were compared to the results from the**
242 **Altona assay (reference standard) used by the UKHSA.**

Candidate Assay	Positive Samples Detected as Positive out of Total	Negative Samples Detected as Positive out of Total	Sensitivity (95% CI)	Specificity (95% CI)
N6/E/MS2	59/60	0/59	98.3% (91.06-99.96)	100% (93.94-100)
N2/N6/MS2	58/60	0/59	96.7% (88.47-99.59)	100% (93.94-100)

243

244 Thus, both assays provided comparable diagnostic performance when compared to a widely used
245 commercial assay. When comparing the two candidate assays, the lower limit of detection and
246 slightly higher observed sensitivity led us to select the N6/E/MS2 assay as the better of the two in-
247 house assays.

248

249 ***Use of N6/E/MS2 assay for detection of SARS-CoV-2 from samples collected in early 2020***

250 The N6/E/MS2 PCR assay was used to detect SARS-CoV-2 in 1803 OPS samples with unknown SARS-
251 CoV-2 infection status collected from healthy (i.e. asymptomatic) 16-18 year-old secondary school
252 students in several sites across the UK between January and March 2020. These samples were
253 collected as part of a large study of the impact of two meningococcal vaccines on throat colonisation
254 in healthy teenagers (3). Of these samples, 4/1803 tested positive on the assay with each positive
255 sample coming from a different site across the UK (Bristol, Cardiff, Glasgow and Maidstone)
256 collected in March. The prevalence across the full study sampling period was 0.2% (95% CI 0.06 –
257 0.57) but in
258 March the incidence was 0.45%; 2 of the 427 (0.47%, 95% CI 0.06% - 1.7%) swabs taken during the
259 week beginning 9th March were positive and 2 of the 459 (0.44%, 95% CI 0.05% - 1.57%) swabs
260 taken during the week beginning 16th March were positive (Supplementary Figure 2). To confirm
261 detection of SARS-CoV-2 and identify strains, sequencing was performed on these samples by COG-

262 UK in Exeter, which identified the samples as being of 3 lineages/clades of the ancestral Wuhan virus
263 (12), results are shown in Table 4. These results suggest that the virus was in circulation at very low
264 levels within secondary schools across England before the first lockdown period was implemented in
265 March 2020.

266

267 **Table 4. Details of the 4 OPS samples identified as positive from samples taken from**
268 **children in March 2020 (total of n=1803 tested) as part of the Be on The Team (BOTT) study.**

BOTT Site	Sample Date	N6/E PCR C_T	Virus lineage as identified by Sequencing (COG-UK, 2020)
Bristol	12/03/2020	28.448	B
Cardiff	16/03/2020	26.981	B.1.1
Glasgow	16/03/2020	28.574	B
Maidstone	10/03/2020	24.697	B.40

269

270

271 ***Detection of SARS-CoV-2 Variants***

272 To confirm comparable detection of the key SARS-CoV-2 variants of interest (relating to different
273 stages of the pandemic) in different respiratory samples, we initially performed 10-fold serial
274 dilutions in culture media of four SARS-CoV-2 variants (Wuhan, Delta, Alpha and Omicron BA.1)
275 which were important at the time. Samples were extracted using QIAsymphony and run on the
276 N6/E/MS2 RT-qPCR assay, and were found to have good detection across the Ct range and suitable
277 efficiency (Supplementary Figure 2). This was repeated more recently using Gamma and Omicron
278 subvariants, including a virus of the JN.1 lineage; similar assay performance was observed for the
279 variants (Figure 2B).



Figure 2. Detection of different SARS-CoV-2 Omicron and Gamma sub-variants with the N6/E/MS2 RT-qPCR assay. Detection of 10-fold serial dilutions of stock of SARS-CoV-2 Gamma strain (light blue dots), Omicron BA.1 (black squares), Omicron BA.2 (red triangles), Omicron BA.4 (green upside-down triangles), and Omicron JN.1 (dark blue diamonds) viruses. The X-axis represents the 10-fold dilution and the y axis the Ct value. The average Ct value for each dilution (3-6 replicates per dilution) is plotted along with the line of best fit after performing a simple linear regression.

The results demonstrate comparable performance for detection for each of the variants tested (also see supplementary Table 1), indicating applicability of the assay for a range of SARS-COV-2 variants representing several time periods since the start of the COVID-19 pandemic.

Discussion

Quantitative RT-qPCR assays remain the gold standard approach for detection of SARS-CoV-2 in clinical samples. Here we present the development, performance characteristics and deployment of a novel dual-target SARS-CoV-2 RT-qPCR assay, N6/E/MS2. The assay demonstrates good accuracy for detection of SARS-CoV-2 in control and clinical samples as well as preserved ability to detect the

299 major SARS-CoV-2 variants including the recently circulating and highly transmissible Omicron JN.1
300 subvariant (13).

301 Since the start of the COVID-19 pandemic, multiple commercial and in-house RT-qPCR assays have
302 been developed for the detection of SARS-CoV-2. As others have reported, we found that sensitivity
303 for detection can be improved by targeting multiple genes (14).. It is thus common for SARS-COV-2
304 RT-qPCR assays to be multiplex, with most currently-used commercial or recommended assays
305 targeting a combination of the E, S, ORF1a and RdRp genes (14, 15). Different regions of the N gene
306 are also common targets, such as in the assays published by the CDC (16). However, the N gene
307 primers presented here are unique and offer high technical performance. With the use of M-Fold
308 and primer3, we demonstrate how use of prediction software packages for the design of novel RT-
309 qPCR assays can achieve high efficiencies and lead to good assay performance. We have also
310 demonstrated the ability of the N6/E/MS2 assay to detect key SARS-CoV-2 variants of concern,
311 including more recently circulating Omicron variant lineages. Conserved performance in these
312 distinct variants of concern may relate to the choice of two distinct target gene regions (N6, E) which
313 have remained relatively conserved in comparison with the S gene (17).

314 To field-test the assay in the early stages of the first UK wave of infections, ~1800 samples from
315 school age children collected in early 2020 (BOTT) were tested, and only four were found to be
316 positive for SARS-CoV-2 (0.2%). Interestingly, these four positive samples were each identified from
317 different sites, suggestive of minimal but widespread transmission of SARS-CoV-2 in UK in this age
318 group at that time, despite the reported number of cases in the UK being only approximately 250 on
319 March 10th rising to ~1,500 cases on March 15th i.e. when the samples were collected (18). This
320 dispersion of isolated cases is supported by global transmission modelling studies that predict that
321 community transmission was probably common in multiple parts of Europe as early as early January
322 2020 (19), and suggest that large numbers of asymptomatic infections went undetected at this time.
323 Furthermore, sequencing data and modelling showed that there were multiple importation events

324 of index cases into the UK in late February/Early March of 2020 from other parts of Europe (20). This
325 is also compatible with our detection of isolated positive cases in 4 distinct locations in the UK more
326 or less simultaneously. The sampling dates of the positive samples were close to the start of the
327 introduction of a national lock down in the UK, on 23rd March 2023 (18), which included school
328 closures. However, given the low rate of infections detected in this cohort, it is unlikely that schools
329 were driving a lot of the transmission at that time.

330 This study has some limitations. Whilst we have tested for sensitivity and specificity compared to a
331 gold standard assay, these data were collected in the early stages of the pandemic, with the
332 ancestral Wuhan virus, and we do not have assay comparison data for later variants. We included an
333 internal RNA control (MS2) to monitor the efficiency of the extraction process. However, unlike
334 other assays we did not include a human control probe to control for effective sample taking. Thus,
335 some negative results observed may have been due to inadequate sampling.

336 In summary, the N6/E/MS2 assay is sensitive and specific for SARS-CoV-2 and has since been used to
337 detect SARS-CoV-2 in respiratory samples collected as part of multiple studies, including a
338 surveillance project in Bristol schools ("CoMMinS") (21), and hospital and community-based
339 surveillance studies of adult lower respiratory tract disease in Bristol, UK ("AvonCAP") (22). As more
340 recent SARS-CoV-2 variants have shown genetic drift, it is important that those using the assay
341 perform regular checks on assay performance with current/recent variants.

342

343 **References**

344 1. Regen F, Eren N, Heuser I, Hellmann-Regen J. A simple approach to optimum pool size for
345 pooled SARS-CoV-2 testing. International Journal of Infectious Diseases. 2020;100:324-6.
346 2. Vogels CBF, Brito AF, Wyllie AL, Fauver JR, Ott IM, Kalinich CC, et al. Analytical sensitivity and
347 efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets. Nat Microbiol. 2020;5(10):1299-
348 305.
349 3. Carr JP, MacLennan JM, Plested E, Bratcher HB, Harrison OB, Aley PK, et al. Impact of
350 meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd
351 protection from the UK MenACWY programme. Clinical Microbiology and Infection.
352 2022;28(12):1649.e1-.e8.

4. Carr J, Plested E, Aley P, Camara S, Davis K, MacLennan JM, et al. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents. BMJ Open. 2020;10(10):e037358.
5. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance. 2020;25(3):2000045.
6. Peters IR, Helps CR, Hall EJ, Day MJ. Real-time RT-PCR: considerations for efficient and sensitive assay design. Journal of Immunological Methods. 2004;286(1):203-17.
7. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, et al. Primer3—new capabilities and interfaces. Nucleic Acids Research. 2012;40(15):e115-e.
8. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Research. 2003;31(13):3406-15.
9. Daly JL, Simonetti B, Klein K, Chen K-E, Williamson MK, Antón-Plágaro C, et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science. 2020;370(6518):861-5.
10. Erdmann M, Williamson MK, Jearanaiwitayakul T, Bazire J, Matthews DA, Davidson AD. Development of SARS-CoV-2 replicons for the ancestral virus and variant of concern Delta for antiviral screening. bioRxiv. 2022:2022.10.11.511804.
11. Quick J. nCoV-2019 sequencing protocol v3 (LoCost) V.3 2020 [Available from: https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bp2l6n26rgqe/v3.
12. Harper H, Burridge A, Winfield M, Finn A, Davidson A, Matthews D, et al. Detecting SARS-CoV-2 variants with SNP genotyping. PLOS ONE. 2021;16(2):e0243185.
13. Yang S, Yu Y, Xu Y, Jian F, Song W, Yisimayi A, et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. The Lancet Infectious Diseases. 2024;24(2):e70-e2.
14. Peñarrubia L, Ruiz M, Porco R, Rao SN, Juanola-Falgarona M, Manissero D, et al. Multiple assays in a real-time RT-PCR SARS-CoV-2 panel can mitigate the risk of loss of sensitivity by new genomic variants during the COVID-19 outbreak. Int J Infect Dis. 2020;97:225-9.
15. Mostafa HH, Hardick J, Morehead E, Miller J-A, Gaydos CA, Manabe YC. Comparison of the analytical sensitivity of seven commonly used commercial SARS-CoV-2 automated molecular assays. Journal of Clinical Virology. 2020;130:104578.
16. Lu X, Wang L, Sakthivel SK, Whitaker B, Murray J, Kamili S, et al. US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis. 2020;26(8):1654-65.
17. Basak S, Kayet P, Ghosh M, Chatterjee J, Dutta S. Emergence of Genomic Diversity in the Spike Protein of the "Omicron" Variant. Viruses. 2023;15(10).
18. Wikipedia. Timeline of the COVID-19 pandemic in the United Kingdom (January–June 2020): Wikipedia; 2024 [Available from: https://en.wikipedia.org/wiki/Timeline_of_the_COVID-19_pandemic_in_the_United_Kingdom_(January%E2%80%93June_2020)#cite_note-56.
19. Davis JT, Chinazzi M, Perra N, Mu K, Pastore YPA, Ajelli M, et al. Cryptic transmission of SARS-CoV-2 and the first COVID-19 wave. Nature. 2021;600(7887):127-32.
20. du Plessis L, McCrone JT, Zarebski AE, Hill V, Ruis C, Gutierrez B, et al. Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK. Science. 2021;371(6530):708-12.
21. Looker KJ, McClenaghan E, Judd A, Pierotti L, Downing H, Phelan J, et al. Acute and long-term outcomes of SARS-CoV-2 infection in school-aged children in England: Study protocol for the joint analysis of the COVID-19 schools infection survey (SIS) and the COVID-19 mapping and mitigation in schools (CoMMinS) study. PLoS One. 2024;19(5):e0303892.
22. Hyams C, Begier E, Garcia Gonzalez M, Southern J, Campling J, Gray S, et al. Incidence of acute lower respiratory tract disease hospitalisations, including pneumonia, among adults in Bristol, UK, 2019, estimated using both a prospective and retrospective methodology. BMJ Open. 2022;12(6):e057464.

Acknowledgements

We acknowledge both the Bristol Genomics Facility and COGG UK (Exeter) as the sequencing providers used for this research. We also acknowledge the Bristol Biobank for support in acquiring control samples for assay development.

Funding

This work was funded in part by University of Bristol Emergency funding awarded to AF and Langford Vets Ltd research funds awarded to PL and CH. AF, ADD, BMA & AH acknowledge funding towards this work from Elizabeth Blackwell Institute, funded in part by the Wellcome Trust [Grant number 204813/Z/16/Z] with additional support from Bristol Alumni and Friends (DARO). We also acknowledge funding via a 2020/21 COVID 19 Research Award Funded by the NIHR Oxford Biomedical Research Centre (BRC) for the testing of the Be On The Team (BOTT) OPS STGG samples.

'Be on the TEAM', 'Evaluating the effect of 'MenB' vaccination on meningococcal carriage', PR-R18-0117- 21001 (BOTT) was funded by the National Institute for Health Research (NIHR) Policy Research Programme. We also acknowledge Meningitis Now funding which enabled the storage and curation of throat swab samples from the Be on the Team study, and The NIHR Oxford Biomedical Research Centre and the Rockinghorse charity, Brighton (RH20-13) who co-funded the SARS-CoV-2 qPCR analysis of the samples.

Competing Interests

AF was lead or co-investigator of several trials of COVID-19 vaccines including the following: Oxford-AstraZeneca, Valneva, Sanofi-GSK. He also was lead or co-investigator on epidemiological studies of SARS CoV2 infection funding by the UK Government and Pfizer.

427 All related research funding was paid to his employer. AF also undertakes paid consultancy
428 for several vaccine manufacturers and developers, although only work for Sanofi relates to
429 COVID-19.